Founder and CEO
AcheneRx LLC
Boston, Massachusetts
Julie is a recognized leader in drug discovery/R&D in the pharmaceutical/biotechnology industry with more than 3 decades of basic research and translational medicine experience in all facets of traditional & novel modality small molecule and biologics drug discovery and development. Prior to becoming an independent consultant, Julie held leadership roles at Merck & Co., Roche and Merck KGaA. Her last industry position was Senior Vice President and head of the Translational Innovation Platform Immunology & Neurology at EMD Serono where she was also the scientific site head at the EMD Serono Research and Development Institute in Billerica, MA to researchers focused on autoimmune diseases, neuroinflammatory disorders, immune-oncology and cancer. Julie has co-authored more than 85 peer-reviewed scientific publications, and is inventor/co-inventor on many patents. Julie founded AcheneRx LLC in 2021 in order to more broadly share her considerable drug discovery & development expertise with students, academic investigators, start-ups, biotechs, pharma, and innovation/investment funds where she seeks to provide non-obvious insights, opportunities and solutions which help expedite, prioritize, and if appropriate, personalize the development or repositioning of novel and/or differentiated mono and combination agents to prevent, treat, and potentially cure debilitating and progressive diseases.
Closing Plenary with Dr. Julie DeMartino
Wednesday, October 25, 2023
4:15 PM – 5:30 PM ET